Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
about
Human cytomegalovirus resistance to antiviral drugsMolecular Basis of Prodrug Activation by Human Valacyclovirase, an -Amino Acid Ester HydrolaseValganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease.Efficacy and safety of low-dose valganciclovir for prevention of cytomegalovirus disease in renal transplant recipients: a single-center, retrospective analysis.Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic stem cell transplantation.Occurrence of adverse events caused by valganciclovir as pre-emptive therapy for cytomegalovirus infection after allogeneic stem cell transplantation is reduced by low-dose administration.Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.Valganciclovir in the treatment of cytomegalovirus retinitis in HIV-infected patients.Management of cytomegalovirus infection and disease in liver transplant recipients.Cytomegalovirus infection of the ileoanal pouch: clinical characteristics and outcomesCytomegalovirus treatment options in immunocompromised patients.Current concepts on cytomegalovirus infection after liver transplantationValganciclovir is an effective prophylaxis for cytomegalovirus disease in liver transplant recipientsCytomegalovirus (CMV) resistance to antivirals.Valganciclovir: A new oral alternative for cytomegalovirus retinitis in human immunodeficiency virus-seropositive individuals.The economic value of valacyclovir prophylaxis in transplantation.Evaluation of the validity of preemptive therapy against cytomegalovirus disease based on antigenemia assay with a cutoff of 20 positive cells per two slides.Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipientsDrug delivery to the retina: challenges and opportunities.Advanced molecular design of biopolymers for transmucosal and intracellular delivery of chemotherapeutic agents and biological therapeutics.Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.Management of opportunistic infections in solid-organ transplantation.Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.Therapeutic applications of hydrogels in oral drug delivery.Detailed polymorphism study on cytomegalovirus DNA polymerase gene to reveal the most suitable genomic targets for quantitative Real-time PCRCytomegalovirus in transplantation - challenging the status quo.Pharmacokinetics of low and maintenance dose valganciclovir in kidney transplant recipients.Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovirAntiviral Chemistry & Chemotherapy's current antiviral agents FactFile (2nd edition): DNA viruses.Population pharmacokinetics of ganciclovir after intravenous ganciclovir and oral valganciclovir administration in solid organ transplant patients infected with cytomegalovirus.New algorithm for valganciclovir dosing in pediatric solid organ transplant recipients.Engineering of a chimeric RB69 DNA polymerase sensitive to drugs targeting the cytomegalovirus enzyme.Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.Strategies for managing cytomegalovirus in transplant recipients.Valganciclovir to prevent or treat cytomegalovirus disease in organ transplantation.Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis.Efficacy of valganciclovir and ganciclovir for cytomegalovirus disease in solid organ transplants: A meta-analysis.
P2860
Q24556634-FAF2DCE1-7607-4593-B4E4-FC8A533DB10BQ27649800-53C06423-A937-49B7-B8B8-E41B0CB31D10Q33363887-6121D2F3-2863-4701-9272-E0619A4ED587Q33364367-21423F1F-EF82-44DA-9552-83D1F74514FDQ33375027-26E2B7DE-C200-4EE5-ACF7-3E0B4A8049FEQ33425731-D1996424-F7E6-45A7-B60E-1FC5DC556491Q33561715-EDB333C1-1B6F-4B03-9DFD-72403062235BQ33715300-21680C3E-49C8-44B8-B8DC-6C165A5B5D3BQ33845124-5A837BDD-D062-4607-9C87-93CF25BFDB5BQ33858240-F52F7DC4-CA33-444C-BCCF-E10727EF2E51Q34390197-70826842-0A72-4BFC-BE1C-E5F3C34E1A6CQ34390310-2CD1F6BE-D042-4C19-BC38-545EF1C0B888Q34413103-C8CF8EE4-9046-4FBE-946C-3FEE858F42E0Q34722194-88A03497-762A-486E-908F-0CB4CA7EE16DQ34834646-979EEFE4-E9D1-4483-9417-8FBAB25EE173Q34918444-3A80C73D-4A59-46F6-9EB2-13A5741DE9AEQ34989242-9B6969EA-8369-4F8D-AE61-529479CF0BDCQ35064406-F1C367DF-5EA7-4B0C-8106-FE0E235EBC6DQ35116140-D4ED136C-719C-4659-A489-5C543C2427C7Q35376573-3C2CF3AE-FE20-4E34-BB43-9A479FE76585Q35571656-8C8960BA-180D-4AF4-A91D-5AE40B491097Q35785403-D663A603-8E62-4637-80FE-F39D6998EF5CQ35841369-8A0F1130-B741-40AD-9A08-0CF2F50432AAQ35871893-DFD63CC5-7BC8-4D19-9991-AF499B3D1901Q35917319-24DD9216-F180-4822-A601-ADB656E10BDFQ35995914-F6083B49-616B-47B2-B9C2-C8E2A09FA48EQ36124353-930EB53A-7A61-40F4-BAF4-8CB87F66541AQ36787493-B9284213-A4C4-4AAD-9D73-C3CC7D7EA480Q36868806-FFFE0592-ABD5-4B6C-A4B2-71551036B13DQ37065216-A17B0D3E-B9D6-466C-80A6-C7601F3A2F66Q37247594-122192A5-D797-451F-8BE2-8F3EED9522EAQ37252268-D560347D-E83A-4A4B-AB84-CEE0249FCB49Q37409907-63F21625-4BFC-4914-A228-C4AFD3C5DB4DQ37432614-D4310695-D289-4F40-A071-3FB4FABF628FQ37446675-76ACB5E1-43CA-4F8C-A599-4302D24C6351Q37724248-75175A86-02C2-46AF-B2DF-450DD7FED13AQ37773992-D7B28861-2F4F-469C-A6BB-EC0A87155245Q37949634-CA558CC8-D09C-4892-9FD1-C8954789CDA6Q38293175-FEE50AC8-ACF9-4A3B-A187-A8B4C7E80606Q38364698-B1CA887A-9119-4A32-8EF1-DDD315CA9AA5
P2860
Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Valganciclovir results in impr ...... in liver transplant recipients
@ast
Valganciclovir results in impr ...... in liver transplant recipients
@en
Valganciclovir results in impr ...... in liver transplant recipients
@nl
type
label
Valganciclovir results in impr ...... in liver transplant recipients
@ast
Valganciclovir results in impr ...... in liver transplant recipients
@en
Valganciclovir results in impr ...... in liver transplant recipients
@nl
prefLabel
Valganciclovir results in impr ...... in liver transplant recipients
@ast
Valganciclovir results in impr ...... in liver transplant recipients
@en
Valganciclovir results in impr ...... in liver transplant recipients
@nl
P2093
P2860
P1476
Valganciclovir results in impr ...... in liver transplant recipients
@en
P2093
C Robinson
M D Pescovitz
R B Freeman
P2860
P304
P356
10.1128/AAC.44.10.2811-2815.2000
P407
P577
2000-10-01T00:00:00Z